Pulmonary hypertension complicating pulmonary sarcoidosis

被引:0
|
作者
M. P. Huitema
J. C. Grutters
B. J. W. M. Rensing
H. J. Reesink
M. C. Post
机构
[1] St. Antonius Hospital Nieuwegein,Department of Cardiology
[2] St. Antonius Hospital Nieuwegein,Department of Pulmonology
[3] UMC Utrecht,Division of Heart and Lung
来源
Netherlands Heart Journal | 2016年 / 24卷
关键词
Pulmonary hypertension; Sarcoidosis; Interstitial lung disease;
D O I
暂无
中图分类号
学科分类号
摘要
Pulmonary hypertension (PH) is a severe complication of sarcoidosis, with an unknown prevalence. The aetiology is multifactorial, and the exact mechanism of PH in the individual patient is often difficult to establish. The diagnostic work-up and treatment of PH in sarcoidosis is complex, and should therefore be determined by a multidisciplinary expert team in a specialised centre. It is still a major challenge to identify sarcoidosis patients at risk for developing PH. There is no validated algorithm when to refer a patient suspected for PH, and PH analysis itself is difficult. Until present, there is no established therapy for PH in sarcoidosis. Besides optimal treatment for sarcoidosis, case series evaluating new therapeutic options involving PH-targeted therapy are arising for a subgroup of patients. This review summarises the current knowledge regarding the aetiology, diagnosis and possible treatment options for PH in sarcoidosis.
引用
收藏
页码:390 / 399
页数:9
相关论文
共 50 条
  • [31] Characterization Of Pulmonary Hypertension Without Elevated Pulmonary Vascular Resistance In Patients With Sarcoidosis: Registry Of Sarcoidosis Associated Pulmonary Hypertension Study (resaph)
    Cordova, F. C.
    Nathan, S. D.
    Barney, J.
    Engel, P.
    Lower, E. E.
    Culver, D. A.
    Baughman, R. P.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [32] Sarcoidosis-Associated Pulmonary Hypertension
    Huitema, Marloes P.
    Mathijssen, Harold
    Mager, Johannes J.
    Snijder, Repke J.
    Grutters, Jan C.
    Post, Marco C.
    [J]. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (05) : 659 - 672
  • [33] AMBRISENTAN FOR SARCOIDOSIS ASSOCIATED PULMONARY HYPERTENSION
    Judson, M. A.
    Highland, K. B.
    Kwon, S.
    Donohue, J. F.
    Aris, R.
    Craft, N.
    Burt, S.
    Ford, H. J.
    [J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2011, 28 (02) : 139 - 145
  • [34] REVERSIBLE PULMONARY-HYPERTENSION IN SARCOIDOSIS
    DAVIES, J
    NELLEN, M
    GOODWIN, JF
    [J]. POSTGRADUATE MEDICAL JOURNAL, 1982, 58 (679) : 282 - 285
  • [35] SARCOIDOSIS AND REACTIVE PULMONARY-HYPERTENSION
    BARST, RJ
    RATNER, SJ
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (11) : 2112 - 2114
  • [36] Global burden of chronic pulmonary aspergillosis complicating sarcoidosis
    Denning, David W.
    Pleuvry, Alex
    Cole, Donald C.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 41 (03) : 621 - 626
  • [37] Pulmonary hypertension and granulomatous vasculitis in sarcoidosis
    Shigemitsu, Hidenobu
    Nagai, Sonoko
    Sharma, Om P.
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2007, 13 (05) : 434 - 438
  • [38] Sarcoidosis-associated pulmonary hypertension
    Cordova, Francis C.
    D'Alonzo, Gilbert
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2013, 19 (05) : 531 - 537
  • [39] Tadalafil For Sarcoidosis Associated Pulmonary Hypertension
    Ford, H. J.
    Baughman, R. P.
    Aris, R.
    Tilley, S. L.
    Engel, P.
    Donohue, J. F.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [40] Clinical predictors of pulmonary hypertension in sarcoidosis
    Bourbonnais, J. M.
    Samavati, I.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2008, 32 (02) : 296 - 302